Compare Delta Air Lines, Inc. (DAL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Moderna, Inc. — how do they compare? Delta Air Lines, Inc. trades at $81.28 (market cap $54.02B), while Moderna, Inc. trades at $221.1 (market cap $78.65B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Delta Air Lines, Inc. pays a 1.05% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Moderna, Inc. for 59 Days on average.
| DAL | MRNA | |
|---|---|---|
Market Cap | $54.02B | $78.65B |
Volume | 9,632,845 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $93.66 | $203.46 |
52-Week Low | $55.65 | $22.36 |
Typical Hold Time | 97 Days | 59 Days |
Enterprise Value | $69.34B | $74.80B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $80.49, down 2.99% on the day, as technical indicators signal bearish momentum with the stock testing support near $80. Fundamentally, the company shows solid profitability with a 5.78% net margin and 20.12% ROE, though Q3 2026 earnings missed expectations. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's in-flight internet instead of Starlink.
The investment outlook remains positive with strong analyst support (82% buy ratings) and a $103.36 consensus price target offering 28% upside. Key risks include fuel cost volatility, rising crew expenses, and competitive threats to premium customer retention. Cash flow trends show improvement with net positive flows since 2024.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
